MetaCap

CareDx Inc. (CDNA)

NASDAQ: CDNAHealth CareMedical SpecialitiesUSD

70.00-1.92 (-2.67%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CDNA stock chart

Technical analysis

Key statistics

All statistics
52-week range
15.56 – 90.87
Day range
69.26 – 72.81
Volume / Avg
781.92K / 1.30M
Beta
—

52-week range

$15.56$90.87

CDNA stock today

Shares of CareDx (CDNA) finished lower on Nov 20 at $70.00, a drop of 2.67% or $1.92 per share, versus the S&P 500's 3.70% decline. At this level, CDNA sits in the middle of its 52-week range of $15.56 to $90.87: 23.0% below the high, set on Oct 30, 2026 and 349.9% above the low. CDNA is up 271.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 307.5%.

At 29.5x trailing earnings, CareDx trades above the peer-group median of 20.5x. Its forward P/E of 44.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About CareDx

Company profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Industry
Medical Specialities
CEO
Mr. John Walter Hanna Jr.
Headquarters
Brisbane, CA
Employees
761
IPO year
2014
Website
caredx.com

Financial highlights

Full financials

In fiscal 2025, CareDx generated $379.8 million in revenue, up 13.8% from fiscal 2024, its 2nd consecutive year of revenue growth. CareDx reported a net loss of $21.4 million, compared with net income of $52.5 million a year earlier. Operating margin was -8.1%.

CareDx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$379.81M$333.79M$280.32M$321.79M$296.40M
Growth+13.79%+19.07%-12.89%+8.57%+54.22%
Net income$-21.35M$52.55M$-190.28M$-76.61M$-30.66M
EPS (diluted)$-0.40$0.93$-3.54$-1.44$-0.59

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$94.43+34.90%

  • Strong buy 1
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $90.00High $100.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$0.35 vs $0.07
Surprise
+400.00%

CDNA news

All CDNA news

CareDx peers

Health Care sector
CDNA peer companies
CompanyPrice% ChgMarket capCompare
ACHCAcadia Healthcare Company Inc.34.60+0.38%$3.22Bvs CDNA
BLLNBillionToOne Inc. Class A89.92-0.31%$4.30Bvs CDNA
GRALGRAIL Inc.99.25-5.33%$4.46Bvs CDNA
CELCCelcuity Inc.53.35-5.26%$2.61Bvs CDNA
CAICaris Life Sciences Inc.17.58-5.18%$5.04Bvs CDNA
CONConcentra Group Holdings Parent Inc.41.84+0.94%$5.26Bvs CDNA
VCYTVeracyte Inc.25.13+0.36%$2.03Bvs CDNA
CLOVClover Health Investments Corp. Class A3.73-1.06%$2.00Bvs CDNA

Indexes, lists and sector

CareDx stock FAQ

What is CareDx's stock price today?

CDNA last traded at $70.00 as of Nov 20, 4:00 PM EST, down 2.67% on the day. Prices are delayed at least 15 minutes.

What is CDNA's P/E ratio?

CDNA trades at a trailing P/E ratio of 29.54 and a forward P/E of 44.75, compared with a median of 20.5 for its closest peers.

Who is CareDx's CEO?

Mr. John Walter Hanna Jr. is the chief executive officer of CareDx Inc., which has about 761 employees.

What is the CDNA 52-week high?

The 52-week high for CDNA is $90.87 and the 52-week low is $15.56. The stock is currently 23.0% below its high.

Compare CDNA